News | March 29, 2022
USFDA approves EUA for second booster dose of Moderna
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Vault PromoMats helps life sciences companies speed the creation, review, and distribution of compliant content. Built-in digital asset management enables content reuse and reduces spend on promotional materials
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
The new glass-free detector has improved durability, is more reliable, and has an improved rugged design to sustain in a high workload environment
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
The survey indicates that 30% of people are still feeling depressed or hopeless on a few days as against GOQii’s last year survey on mental Health where 43% of Indians were depressed
The expansion makes Exothera one of the largest viral vector facilities in Europe
Subscribe To Our Newsletter & Stay Updated
